Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis

Masafumi Myoishi, Satoshi Yasuda, Shunichi Miyazaki, Kazuyuki Ueno, Isao Morii, Kazuhiro Satomi, Yoritaka Otsuka, Atsushi Kawamura, Takashi Kurita, Shiro Kamakura, Hiroshi Nonogi

研究成果: Article査読

12 被引用数 (Scopus)

抄録

Excretion in the urine is an important pathway for the elimination of nifekalant hydrochloride (NIF), a novel class III antiarrhythmic agent. Three patients with renal failure were undergoing hemodialysis and receiving NIF for the prevention of ischemia-induced ventricular tachyarrhythmia. Because NIF is not dialyzed, dose adjustment at relatively low concentrations was required, with monitoring of the QT interval.

本文言語English
ページ(範囲)898-900
ページ数3
ジャーナルCirculation Journal
67
10
DOI
出版ステータスPublished - 2003 10 1
外部発表はい

ASJC Scopus subject areas

  • 循環器および心血管医学

フィンガープリント

「Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル